Bio-IT World News
YouTube Facebook LinkedIn TwitterInstagram rss
a-divisiion-of-chi
  • Subscribe
  • News
    • Latest News
    • View Press Releases
    • Post a Press Release
    • Reprint Articles
  • Podcast
  • Advertise
    • Media Kit
    • Digital Advertising
    • Lead Generation
    • Editorial Calendar
    • Webinars
    • Whitepapers
    • Podcasts
    • View Press Releases
    • Post a Press Release
  • Free Downloads
    • Whitepapers
    • Podcasts
    • Webinars
    • Inside eBooks
  • Events
    • Webinars
    • Industry Events
    • IT Conferences
    • Bio-IT World Expo
    • Bio-IT World Expo Europe
  • About Us
    • Editorial Profile
    • Editorial Calender
    • Contact Us
    • Submit a story
    • Innovative Practices Awards
    • Linking Policy
  • Bio-IT World Expo
    • Bio-IT World Boston
    • Bio-IT World Europe
 
 
 
 
  • How Much Does it Cost to Develop a Drug

    Nov 18, 2014, 00:00 AM by Michael Croft
    Pharmalot | Later today, the Tufts Center for the Study of Drug Development will release a report that will take yet another stab at determining the true cost of developing a medicine. In the meantime, Ed Silverman is running a poll.
    Full story
  • Definiens Predicts Biggest Drivers for Personalized Medicine in 2015: Data Quality, Immunotherapy, Combination Treatments and Predictive Biomarkers

    Nov 18, 2014, 00:00 AM by Michael Croft
    MUNICH, GERMANY - Nov 18, 2014 - Major opportunities are on the horizon for personalized medicine and clinical cancer research and treatment, according to Definiens, the global leader in Tissue Phenomics® for oncology diagnostics
    Full story
  • Top500 Supercomputer Listing With Minimal Changes

    Nov 17, 2014, 15:00 PM by Michael Croft
    Computerworld | The latest Top500 list is out, but only one new system made it into the top ten. The Chinese Tiahne-2 has kept its number on position for the fourth time, even though it has not changed its computing power.
    Full story
  • Vytorin, LDL-Targeting Drugs Work

    Nov 17, 2014, 11:00 AM by Michael Croft
    Bio-IT World Roundup | The results of the IMPROVE-IT trial were announced today, a seven-year study looking at whether Merck's Vytorin and Zetia pills actually prevent heart attack. The answer: yes. At least some.
    Full story
  • Medidata Collaborates with GlaxoSmithKline on Mobile Health Initiative to Test Novel Technology for Clinical Trial Optimization

    Nov 17, 2014, 00:00 AM by Michael Croft
    NEW YORK, NY, UNITED STATES OF AMERICA - Nov 17, 2014 -  Medidata (NASDAQ: MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, today announced the completion of a method development project conducted in partnership with GlaxoSmithKline plc (GSK) to evaluate the impact of unifying mobile health (mHealth) devices with cloud-based technologies in a clinical trial setting
    Full story
  • National Labs Buying Next-Gen IBM Supercomputer

    Nov 14, 2014, 12:00 PM by Michael Croft
    Nature | Oak Ridge National Laboratory (ORNL) in Tennessee and the Lawrence Livermore National Laboratory in California announced today their plans to upgrade to a next-generation IBM supercomputer that will run at 150 petaflops.
    Full story
  • Google Increases Award in 'Nobel' Prize of Computing

    Nov 14, 2014, 08:00 AM by Michael Croft
    Mashable | Google has raised the stakes in the A.M. Turing Award, offering $1 million. The annual awards recognize "major contributions of lasting importance to computing," and until now have included a cash prize of $250,000.
    Full story
  • 11beta-HSD1 focused library from OTAVA

    Nov 14, 2014, 00:00 AM by Michael Croft
    VAUGHAN, ON - Nov 14, 2014 - 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1, 11beta-HSD1) is an NADPH-dependent enzyme, which catalyses conversion of inactive glucocorticoids 11-dehydrocorticosterone and cortisone to active corticosterone and cortisol and vice versa
    Full story
  • IBM Invests in Pathway Genomics' Watson-Powered Health App

    Nov 13, 2014, 08:00 AM by Michael Croft
    Bio-IT World | Pathway Genomics yesterday announced an investment from IBM to launch Pathway Panorama, a health-focused mobile app powered by IBM’s Watson’s natural language processing technology and fed by data from Pathway Genomics’ genetic tests.
    Full story
  • Inactivated Protein Lowers Risk of Coronary Heart Disease by 53%

    Nov 12, 2014, 15:00 PM by Michael Croft
    Bio-IT World | A sequencing study published tomorrow in the New England Journal of Medicine has further characterized the activity of the Niemann-Pick C1-like 1 protein (NPC1L1). Carriers of inactivating mutations of NPC1L1 were found to have a 53% lower risk of coronary heart disease and an average LDL cholesterol level 12 mg per deciliter lower than that of noncarriers.
    Full story
  • ARUP Laboratories and PierianDx Create Partnership to Produce More Efficient and Effective Diagnostic Genetic Tests

    Nov 12, 2014, 00:00 AM by Michael Croft
    SALT LAKE CITY AND ST LOUIS, MO, US - Nov 12, 2014 - ST LOUIS and SALT LAKE CITY (Nov. 12, 2014) – ARUP Laboratories and PierianDx announced today a partnership that will result in faster and more efficient diagnostic genetic testing for thousands of patients across the U
    Full story
  • De Novo Human Genome Assembly Using Long Reads

    Nov 10, 2014, 13:40 PM by Michael Croft
    Bio-IT World News Brief | Evan Eichler of the University of Washington and colleagues have published a paper in Nature detailing a new whole human genome assembly, using the long-reading SMRT sequencing technology of Pacific Biosciences.
    Full story
  • Breakthrough Prizes Highlight CRISPR Gene Editing, Gene Regulation

    Nov 10, 2014, 11:10 AM by Michael Croft
    Bio-IT World | Emmanuelle Charpentier and Jennifer Doudna, co-discoverers of the CRISPR-Cas9 mechanism that has swiftly become a groundbreaking tool in genetic engineering, are among this year's winners of the $3 million Breakthrough Prizes in the Life Sciences awarded by a coalition of tech billionaires.
    Full story
  • BaseHealth CEO Jorge Velarde Speaks About the New Market for Genomic Health

    Nov 7, 2014, 10:05 AM by Michael Croft
    Bio-IT World | As a new crop of patient-facing genomic health companies adjusts to cheaper DNA data and more intense FDA oversight, Jorge Velarde, a former Illumina executive and the new CEO of BaseHealth, tells Bio-IT World what we can expect from this second wave of interest in our genomes' influence on health.
    Full story
  • CREBBP focused library from OTAVA

    Nov 7, 2014, 00:00 AM by Michael Croft
    - Nov 7, 2014 - CREB-binding protein (CREBBP, CBP) is a transcriptional coactivator of a broad range of transcription factors
    Full story
  • Genome Storage for $25

    Nov 6, 2014, 15:00 PM by Michael Croft
    Technology Review | Google Genomics says it is storing at least 3,500 genomes at the rate of $25 per genome per year. The analytics cost extra.
    Full story
  • What a Big Data Buy Could Mean

    Nov 6, 2014, 15:00 PM by Michael Croft
    ReadWrite | One acquisition in the Big Data space could change everything, one analyst predicts, pointing out that if Oracle or Cisco were to snap up one of the Big Data start-ups the collateral damage would be severe.
    Full story
  • Google to Cover Foundation Medicine Tests for All Employees

    Nov 6, 2014, 10:05 AM by Michael Croft
    BetaBoston | Foundation Medicine, the largest and most visible provider of broad genetic tests for personalized cancer therapy, announced this week that Google will pay for its tests for anyone covered under Google health plans.
    Full story
  • MolecularHealth to Speak at the 10th Annual Personalized Medicine Conference

    Nov 6, 2014, 00:00 AM by Michael Croft
    THE WOODLANDS, TX, UNITED STATES - Nov 6, 2014 - MolecularHealth announced today that Medical Director Gabriel Bien-Willner, M.D., Ph.D., will speak at this year’s Personalized Medicine Conference
    Full story
  • AstraZeneca Buys Definiens in Bid for Ground-Up Co-Diagnostics Pipeline

    Nov 5, 2014, 09:05 AM by Michael Croft
    Bio-IT World News Brief | AstraZeneca announced that it has acquired Definiens, a diagnostics company specializing in image analysis software, as part of a strategy to refine its immuno-oncology programs.
    Full story
  • «
  • 391 (current)
  • 392
  • 393
  • 394
  • 395
  • 396
  • 397
  • 398
  • 399
  • 400
  • »
 
CHI | Cambridge HealthTech Institute

250 First Avenue, Suite 300
Needham, MA 02494

P: 781.972.5400
F: 781.972.5425
E: chi@healthtech.com

Life Science Portals

Biological Therapeutic Products

Biomarkers & Diagnostics

Biopharma Strategy

Bioprocess & Manufacturing

Chemistry

Clinical Trials &
Translational Medicine

Drug & Device Safety

Drug Discovery & Development

Drug Targets

Healthcare

IT, AI, ML & Informatics

Technology & Tools For
Life Science

Therapeutic Indications

Venture, Innovation & Partnering

CHI Divisions

Conferences

Reports & Market Research

Barnett Educational Services

News & Advertising

Professional Services

Corporate Information

Cambridge Innovation
Institute

Executive Team

Testimonials

Mailing List

Careers


Request Information

Privacy Policy